Business Wire

MA-BRIGHTCOVE

2.12.2021 15:02:14 CET | Business Wire | Press release

Share
ENTERPRISE AND MEDIA ORGANIZATIONS DRIVE REVENUE, ENGAGEMENT, AND DEMAND WITH BRIGHTCOVE SOLUTIONS, INDEPENDENT STUDY REVEALS

Brightcove Inc. (Nasdaq: BCOV), the global leader in video for business, released findings that enterprises and media organizations can generate 225% and 226% ROI respectively with Brightcove and see a full return on the initial investment in less than six months. The commissioned Total Economic Impact™ (TEI) studies conducted by Forrester Consulting examined cost savings and business benefits with Brightcove solutions for enterprise and media organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005560/en/

Forrester Consulting interviewed decision-makers at multiple enterprise and media organizations with experience using Brightcove. Respondents came from organizations headquartered in the US and EMEA, all with multi-billion dollars of annual revenues. The enterprise interviewees represented industries including automotive manufacturing, technology manufacturing, and media services that primarily use video to sell products and services and train their employees. The media organizations’ interviewees represented decision-makers at media organizations already using Brightcove to stream and monetize their content.

Enterprise ROI

The study found that after the investment in Brightcove, the interviewees’ organizations gained increased insights, reduction in management and distribution time of content, and most importantly increased digital engagement. Decision-makers who deployed the videos hosted by the Brightcove platform in conjunction with revenue-generating offerings found that their organization could use the analytics Brightcove provided to adapt their content to meet the needs of their different audiences whether employees, customers, or partners. Prior to using Brightcove, enterprises had disjointed video management solutions and workflows and strived for improved analytics, the ability to scale content, and syndicate videos for distribution to any source.

One platform product manager in the technology manufacturing sector cited Brightcove’s user experience and easy-to-use interface as considerably better than their previous video provider's solution. Their team realized they could globalize videos more quickly with multilingual metadata, whereas before the team needed to manually change titles, thumbnails, and subtitles. As part of an organization that operates in 27 locales, the team now spends less time on manually translating videos, and more time focusing on high-value workflows, such as content creation and campaign strategy.

Multiple users cited the benefits of Brightcove’s user experience and easy-to-use interface, the business impact of which includes savings on resource expenditure through content management efficiencies including:

  • 80% reduction in time it takes to migrate content with advanced processing power
  • 83% reduction in time spent on manual content management tasks
  • 50% reduction in spend for additional content distribution and management
  • 75% reduction in video syndication time

Media ROI

As media organizations search for ways to expand their offerings globally, there is an increased need for superior video quality, faster time to market, and ways to monetize their content. The study found that media customers that use the Brightcove platform can better distribute and monetize live and on-demand video content on multiple platforms more securely and reliably. Prior to using Brightcove, media organizations missed expansion opportunities due to technical complexities like slow transcoding times, failure and downtime during peak demand, and time-consuming quality assurance processes.

With Brightcove’s platform, media organizations are able to expand more easily to new markets and devices through faster transcoding of content, more reliable content processing, and improved end-viewer experiences resulting in increased customer lifetime values.

A global head of media technology at a media/entertainment organization, commented on Brightcove’s constant technology enhancements, resulting in better quality with more bandwidth. After switching from their legacy solution to Brightcove, they noticed a significant increase in quality for their audiences.

Other key outcomes for media organizations include:

  • 15-25% increase in potential audience over modeled period
  • 80% reduction in time to migrate content to improve ability to scale
  • 83% reduction in time spent on manual content management tasks
  • 75% reduction in the number of compliance violations

“Companies know that video is THE most effective way of connecting with their audiences. Too frequently, however, companies have not been able to quantify the business benefits or even know what metrics they should be targeting to improve,” said Jennifer Griffin Smith, CMO, Brightcove. “Forrester’s findings provide guidance into the key areas of opportunity for our customers including improved user engagement, increased audience acquisition, new market expansion, and revenue generation. It also highlights, in our opinion, the experience we have at Brightcove in helping companies scale their operations more effectively and measure business impact.”

To read the Forrester Total Economic Impact™ study, visit https://www.brightcove.com/en/resources/downloads/studies/forrester-tei-study/

About Brightcove Inc.

Brightcove creates the world’s most reliable, scalable, and secure video technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 70 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on Twitter , LinkedIn , and Facebook . Visit www.brightcove.com . Brightcove. Video that means business™.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye